期刊文献+

髓过氧化物酶与急性冠脉综合征的相关性 被引量:4

下载PDF
导出
摘要 急性冠脉综合征(acute coronary syndrome,ACS)的发病基础是不稳定斑块的形成、破裂、炎症反应、血小板聚集、继而血栓形成,使冠状动脉部分或完全阻塞,造成心肌急剧的缺血缺氧,而表现出一系列的临床综合征。随着炎症参与ACS发病机制研究的不断深入,特别是髓过氧化物酶(myeloperoxidase,MPO)作为其中最为代表性的炎症标记物正逐渐受到人们的关注。已有大量证据表明,在不稳定斑块内有大量髓过氧化物酶及其氧化物聚集,即可考虑髓过氧化物酶作为一种炎性介质参与不稳定斑块的形成与发展,而且对于冠心病的危险分层也具有十分重要的价值。该文结合最近国内外关于MP0与冠心病的研究作一综述。
作者 范园春 夏鹄
出处 《安徽医药》 CAS 2014年第5期800-803,共4页 Anhui Medical and Pharmaceutical Journal
  • 相关文献

参考文献22

  • 1Liu C,Xie G, Huang W, et al. Elevated serum myeloperoxidase ac- tivities are significantly associated with the prevalence of ACS and High LDL-C levels in CHD patients [ JJ. J Atheroscler Thromb, 2012,19(5) :435 -443.
  • 2Sawicki M, Sypniewska G, Kozinski M, et al. Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes[ J]. Eur J Elin Invest,2011,41 (6) :667 -671.
  • 3Graner M,Tikkanen E, RimpilO, et al. Diagnostic efficacy of my- eloperoxidase to identify acute coronary syndrome in subjects with chest pain[ J. Ann Med,2013,45 (4) :322 - 327.
  • 4Shao B, Oda MN, Oram JF, et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein I J ]. Chem Res Toxico1,2010,23 ( 3 ) :447 - 454.
  • 5Scbindhelm RK, van der Zwall l,P, Teerlink T, el al. Myeloperoxi- dase:A Usetul Biomarker for Cardiovascular Disease Risk Stratifi- cation? [J]. Clin Chem,2009,55(8) :1462 - 1470.
  • 6王亚男,陆林,张瑞岩,张奇,胡健,杨震坤,陈秋静,沈卫峰.急性冠脉综合征血清CC趋化因子19、21和髓过氧化物酶的改变[J].国际心血管病杂志,2011,38(3):184-186. 被引量:1
  • 7严炳存,石延科,彭海军,高锦雄,袁春雷,徐蕾,李明光,梁碧霞.冠心病患者血浆中MPO水平与冠心病及其严重性的相互关系[J].吉林医学,2013,34(18):3547-3548. 被引量:1
  • 8Roman RM, Wendland AE, Polanczyk CA. Myeloperoxidase and coronary arterial disease :t'om research to clinical practice[ J]. Arq Bras Cardio1,2008,91 ( 1 ) :e11 - e18.
  • 9Roman RM, Camargo PV, Borges FK, et al. Progm)stic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients [ J]. Coron Artey Dis, 2010,21 ( 3 ) : 129 - 136.
  • 10Baldus S, Heeschen C, Meinertz T, et al. CATURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute eor- ona' syndromes [ J 3. Circulation ,2003,108 ( 12 ) : 1440 - 1445.

二级参考文献38

  • 1卢桂静,刘文龙,李方雄,张国刚,杨天伦,Berglund L.冠心病稳定性心绞痛患者血浆髓过氧化物酶的变化[J].中华老年医学杂志,2006,25(11):829-831. 被引量:11
  • 2欧阳茂,杨侃,张梦玺,蒋卫红,曹宇,王建刚,高应冬.血浆髓过氧化物酶在急性冠脉综合征中的临床意义[J].中南大学学报(医学版),2006,31(6):901-905. 被引量:6
  • 3Hermus L, Lefrandt JD, Tio RA, et al. Carotid plaque formation and serum biomarkers [J]. Atherosclerosis, 2010, 213 ( 1 ) 21-29.
  • 4Erbel C, Sato K, Meyer FB, et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque[J].Basic Res Cardiol, 2007, 102(2):123 -132.
  • 5Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain[J]. N Engl J Med, 2003, 349 (17): 1595- 1604.
  • 6Ni W, Kitamoto S, Ishibashi M, et al, Monocyte chemoattractant protein- 1 is an essential inflammatory mediator in angiotensin Ⅱ Induced progression of established atherosclerosis in hypercholesterolemic mice[J]. Arterioscler Thromb Vasc Biol, 2004, 249(3) : 534-539.
  • 7Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease:Update 2010[J]. Am Heart J, 2(110, 16(1(4) : 583-594.
  • 8Rana JS, Arsenault BJ, Despres JP, et al. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women [J]. Eur Heart J, 2011, 32(3):336-344.
  • 9Goldmann BU, Rudolph V, Rudolph TK, et al. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction[J].Free Radic Biol Med, 2009, 47( 1 ) : 79-83.
  • 10Apple FS, Smith SW, Pearce I.A, et al, Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations [J]. Clin Chem, 2011, 57(4) :603- 608.

共引文献8

同被引文献46

  • 1方玉强,黄岚,李爱民,宋耀明,晋军,耿昭华,于学军,邓梦杨.循环内皮脂酶阳性细胞比例与超敏C-反应蛋白在冠心病患者临床预后中的作用[J].中国危重病急救医学,2007,19(11):644-646. 被引量:13
  • 2Alhadi HA, Fox KA. Do we need additional markers of myocytenecrosis : the potential value of heart fatty-acid-binding protein[J]. QJM,2004,97 (4) : 187-198.
  • 3Chan CP, Sanderson JE, Glatz JF, et al. A superior earlymyocardial infarction marker. Human heart-type fatty acid-binding protein [ J ]. Z Kardiol,2004,93 (5) : 388-397.
  • 4Tousoulis D, Kampoli AM, Stefanadi E, et al. New biochemicalmarkers in acute coronary syndromes [ J ] . Curr Med Chem,2008,15 (13): 1288-1296.
  • 5Pope JH, Aufderheide TP, Ruthazer R,et al. Missed diagnoses ofacute cardiac ischemia in the emergency department [ J ]. N EnglJ Med,2000,342 ?16) : 1163-1170.
  • 6Bonaca MP, Morrow DA. Defining a role for novel biomarkersin acute coronary syndromes [ J ]. Clin Chem,2008,54 (9):1424-1431.
  • 7Gravning J, Kjekshus J. The perfect biomarker in acute coronarysyndrome : a challenge for diagnosis,prognosis,and treatment [ J ].Eur Heart J,2008,29 (23) : 2827-2828.
  • 8Vancouver BC. International Academy of Cardiology 18th WorldCongress on Heart Disease Annual Scientific Sessions 2013 [ J ].Cardiology,2013,125 (Suppl 2) : 1-510.
  • 9Schittek B, Hipfel R, Sauer B, et al. Dermcidin : a novel humanantibiotic peptide secreted by sweat glands [ J ]. Nat Immunol,2001,2(12):1133-1137.
  • 10Ghosh R, Karmohapatra SK, Bhattacharyya M,et al. Theappearance of dermcidin isoform 2,a novel platelet aggregatingagent in the circulation in acute myocardial infarction that inhibitsinsulin synthesis and the restoration by acetyl salicylic acid of itseffects [ J ]. J Thromb Thrombolysis,2011,31 (1) : 13-21 .

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部